

**How I
started to
save human
being**

HealthCare



Intelligent Solution for Early Stage
Prediction of
Cardiovascular Disease Using
Machine Learning
and Multi-Agent Technology



AJNA

Next Generation Clinical Analytics

Agenda



- Background
- Problem Domain
- Aim
- Objectives
- Previous Works
- High-Level Architecture Diagram
- Methodology
- Testing
- Research Findings
- Contributions
- Conclusion



AJNA

Next Generation Clinical Analytics





**AJNA -
Intelligent Solution for Early Stage
Prediction of
Cardiovascular Disease Using
Machine Learning
and Multi-Agent Technology**



M.M.A. Gayan Samuditha

B.Eng. (Hon's) Software Engineering



Supervised By

Achala Chathuranga Aponso

B.Eng. (Hon's) Software Engineering, (University of Westminster, UK)

M.Sc. : Artificial Intelligence (University of Moratuwa, SL)

PhD : Multi-Agent Systems (Reading), (Monash University, AU)





Machine Learning & Multi-Agent Systems

Background

AI



- Background




- Cardiovascular disease (CVD) is a class of diseases that involve the heart or blood vessels. CVD includes coronary artery diseases (CAD) such as angina and myocardial infarction (commonly known as a heart attack).
- Other CVDs include stroke, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, heart arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease, thromboembolic disease, and venous thrombosis.



HEALTH
INNOVATIONS

Top 10 global causes of deaths, 2016




Source: Global Health Estimates 2016: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2016, Geneva, World Health Organization, 2018.

[WHO reports on top 10
deadly diseases in 2018
survey facts.](#)

“According to the World Health Organization (WHO) statistics shows cardiovascular disease represents, approximately death of 17.9 million of deaths rate in 2015 which represented 31% of all global deaths (WHO, 2018). It mostly highlight the developing countries in the world ”

AI



Research Problem


- General Research Problem
- Specific Research Problem

General Research Problem Background

- These clinical trials consist of different laboratory reports, scanning reports, ECG reports, physician's symptom and examination diagnose reports, demographic factors, scan reports raw data etc. (Ambrosy et al., 2014, p1123–1133).
- Clinical records as electronic health records (EHR data). EHR data are the mostly all these clinical records that include vary of raw data on clinical trials (Kini et al., 2017, p628–640).
- More explanation on EHR data, it provides huge quantity of data and technically it considers as big data.
- There are millions of big data (Electronic health records) collecting by hospitals, clinical centers daily.
- More consider about that technical processes, it will help to analyze these EHR data for do the same manual diagnosis can done by autonomously using machine learning based algorithms in minimum time (Denaxas et al., 2012, p1625–1638).



Traditional Clinical Diagnosis of Cardiovascular Disease



Cardiovascular System



• Clinical Diagnosis Stage 01:

1. Patient's initial complaint stage, upon first appointment to the doctor,
2. Patient will explain the symptoms (problems) using their own words.
3. Symptom diagnosis processes.
4. Then physician compares between these answers from patient and diagnosis process, physician will write the diagnosis points on patient's clinical description.

Clinical Stage Conclusion: *If it is not completely obvious to the doctor, the disease is not yet diagnosed.*

• Clinical Diagnosis Stage 02:

1. After the first stage of diagnosis, then physicians will check patient again.
2. More information about the disease.
3. Checking how far the cardiac symptoms were developed and the patient's condition. Questioning the patient with current diagnosis status
4. Patients will move to the next clinical stage to examine the patient by cardiovascular specialist.

Clinical Stage Conclusion: *The new diagnosis has been pointed down to a few diseases and for further specific diagnosis, physicians will move the patients to cardiovascular specialist for further disease diagnosis*

Specific Research Problem Overview

- Most traditional methods that developed for disease prediction approaches have been used statistical regression-based models.
- Although useful and vigorous of these traditional statistical models are limited to using a minor number of predictors which apply for the same way on everyone and eventually throughout their range (G et al., 2013).
- Not only that, the complexity of the diagnosis process and human interconnect manual processes are time consuming and inefficient (Singh et al., 2018, p121–124).




Specific Problem Statement

“The problem of the physician has long needed to identify, analyze, quantify and clarify the relationships among feature variables (Clinical trials) to advance progress for patient care. Does it can practically do in manually way for early-stage prediction of Cardiovascular Diseases for all patients individually? How to improves these processes using high-quality diagnosis processes with machine learning based artificial intelligence techniques to solve these problems accurately.”



AI

Aim of the Research




The Aim of the Research

“This research project aims to design, develop and evaluate an Artificial Intelligence-based autonomous prediction engine to assist physicians (Cardiothoracic Surgeons and Cardiologists) at the point of patient care; interact with the system to help diagnosis, analysis and early stage prediction of Cardiovascular Diseases of using patient’s clinical history data.”





Proposed Solution



Objectives of the Research

Research Objectives – Cardiovascular disease diagnose modelling

Objective

To identify all diverse pathways to end-stage Cardiovascular Disease

Analyze the availability of existing computer aided cardiac models

Implement Machine Learning based AI prediction engine

Apply the diagnosis models to prediction engine and analyze

Evaluate the prediction engine using patient's clinical history

Technical Objectives – Technical Perspectives and Design Model Architecture

Objective

To identify the specific risk factors on Cardiovascular

Analyze the risk factors

Survey on best machine learning algorithms

Analyze the model for selecting the best machine learning algorithms

Analyze the ML decision model

Implement the model using machine learning techniques and data mining concepts

Evaluate the prediction engine



- **Research Level Cardiovascular Prediction Tools:**

- Used for research level analysis of cardiovascular risk predictions. Most of these tools developed by research-based institutions for research level purposes.
- Deployed to some healthcare authorities to test the tool accuracy levels and overcome.
- Most of the research level prediction tools are limited to their already associated healthcare centers and hospitals etc. These types of tools did not deploy for production level.

* Research Level Tools: QRISK, QRISK2, QRISK3, SCORE etc.



- **Production Level Cardiovascular Prediction Tools:**

- There are limited number of tools were introduced for production level cardiovascular risk prediction.
- Introduced by IBM Watson research center, California, USA.
- Most of the tools were used by hospitals, medical care centers and other healthcare facilities.

* Production Level Tools: IBM Watson Care Manager, Merge Cardio etc.



Research Level Cardiovascular Prediction Tools

WELLPOINT now running QRISK3



Wellpoint
Kiosks



Online
Assessments



Analytics
& Data Hub

QRisk®3 Heart Age Questionnaire

Please answer the questions below.

Navigate through the questions using the Next and Previous buttons.
When you get to the end of the questionnaire, press the 'Finish' button

[Back to Dashboard](#)

Thank you for completing this questionnaire.




Your risk of having heart disease in the next 10 years is Low



Research Level Cardiovascular

Prediction Tools



IBM Watson Care Manager (Watson Care Manager, 2019)
<ul style="list-style-type: none">IBM Watson Care Manager is cloud based healthcare management systemhelp the healthcare organizations to focus on patient care.Care teams can capture the clinical details both unstructured and structured information, selected programs and create individualized care plans for patients.These care plans can be adjusted to address changing biological, social, physiological and functional needs.
Features
<ul style="list-style-type: none">Care management workflowsHealth Summary ReviewThird-party system integration
IBM Watson Oncology Clinical Trail Matching (2017)
Watson oncology clinical trial matching platform provide clinicians to more easily and quickly find the patients clinical trials. Then it helps to coordinate clinical trials,
Features
Analyzes structured and unstructured patient’s data
Support proactive patient identification
Identifies a list of relevant trial options




Key Findings – Literature Review

- Identify the Cardiovascular Clinical Processes.
- Research Level Existing Systems vs Production Level Existing Systems.
- Electronic Health Records (Clinical Data).
- New concepts of Machine Learning models and Algorithmic Analysis.
- Binary Classification Approaches :

Supervised Learning – Classification (TensorFlow and Kera's)

- Reinforcement Learning Concepts
- Multi-Agent Technologies in Cardiovascular Disease Management
- Multi-Agent Learning in Prediction Environment (Reinforcement Learning Environment)



System Requirement Specification

Domain Expert Surveys

- Cardiology Domain Expert Survey
- Machine Learning & Multi-Agent Systems Domain Expert Survey

Formal Interviews with Domain Experts

- Cardiology – Cardiothoracic Domain Experts (Physicians)
- **Cardiovascular Domain Expert (Specialize in Cardiovascular Medical Research)**
- Machine Learning – Domain Experts
- Multi-Agent Systems – Domain Experts





SLEP Analysis

Social Analysis: -

- Impacts on the individual's patient's health profile, when unwanted parties notice the proposed health status.
- Unexpected struggles/disputes.

Legal Analysis: -

- Patients Clinical Reports Infraction.
- Computer Misuse Act Violation

Technological Analysis: -

- Technological developments specific for hospitals and healthcare manufactures could have a changeable range of effects on system overall performance

Ethical Analysis: -

- Patients clinical history and reports contravention (Privacy Breaches)
- Overhearing – Patients health status

Professional Analysis: -


- Health Data code of conduct comply to the published guidelines, conducts and policies of the institution in Sri Lanka, when specify the research protocol guidelines.

Economic Factor Analysis: -

- Considering about the product cost deliverable when it comes to production level.



High-Level Architecture






MULTI-AGENT SYSTEM

Multi-Agent Communication Architecture

- How agent-communication working?
- Intelligent Agents of Multi-Agent Systems
- E Jabbered Server – XMPP Server Connections with Visualizations
- Data visualizations with agent systems






Dr. Zahra Alizadeh Sani

Associate Professor of Cardiology / Cardiovascular imaging Specialist
Cardiovascular Imaging Department,
Rajaei Cardiovascular Medical & Research Center,
Iran University, Tehran, Iran.

For too long, patients and healthcare ecosystems
have been largely disconnected.



Intelligent Solution for Early Stage Prediction of Cardiovascular Disease Using Machine Learning and Multi-Agent Technology





AJNA

Next Generation Clinical Analytics



Testing Process – AJNA Platform





Testing – Cardiovascular Prediction Module

Measure	Value
Accuracy	73%
F1 Score	0.844490
Precision	0.730838
Recall	0.953478

Summarization of Accuracy Report

	Predicted (NO)	Predicted (YES)
Actual (NO)	TN=281	FP=21
Actual (YES)	FN=7	TP=813

Confusion Matrix



True Positives (TP)

Predicted value = Positive
Actual value = Positive



True Negatives (TN)

Predicted value = Negative
Actual value = Negative



False Positives (FP)


Predicted value = Positive
Actual value = Negative




False Negatives (FN)

Predicted value = Negative
Actual value = Positive


Cardiovascular Prediction Module – Accuracy Testing




ROC Curve



ROC Curve (Top left)



Model Accuracy Training Graph



Model Training Loss Graph



AJNA – Platform Benchmarking



Tool Name	Feature Overview
IBM Watson – Oncology (IBM Watson for Oncology, 2017)	“Helps physicians quickly identify key information on a patients’ medical record, surface relevant evidence and explore treatment options.”
Watson Clinical Reviewer (IBM Watson Imaging Clinical Review, 2018)	“This tool is a retrospective AI-enabled data review tool that helps support a reliable patient record in order to drive accurate, timely and coordinated care decisions.”
IBM Watson - Care Manager (Watson Care Manager, 2019)	“Handles the patient’s clinical records and automate care management workflows.”
Watson – MERGE CARDIO (Merge Cardio, 2019)	“Merge Cardio allows you to access and manage your patients’ digital integrated cardiovascular records from a centralized, web-enabled system, anywhere, any time.”
Watson – MERGE HEMO (Merge Hemo, 2018)	“Merge Hemo automates your cath lab process – including data collection, waveform analysis, inventory control and procedural reporting – into a comprehensive digital patient record.”



Domain Expert Evaluation



DR. NAMAL GAMAGE
Senior Cardiothoracic surgeon

Dr. Namal Gamage

Cardiothoracic Surgeon

Cardiothoracic Unit – Teaching Hospital
Karapitya, Galle



Dr. Saad Khan

Senior Software Engineer - HIRETUAL

PhD – Specialize in Microservices, Serverless
Computing, Machine Learning and Multi-agent
Systems
University of Central Florida



Dr. Kushan Gunarawardhana

Research Scientists – Cardiovascular Medicine

Yale Cardiovascular Research Center
PhD – Specialize in Bioinformatics and Molecular
Biology,



Dr. Mano Mathew

Associate Professor, Head of the Bioinformatics, EFREI, Paris

PhD – Specialize in Bioinformatics
Aix-Marseille University, France



Dr. Isuru Daulagala

Software Engineer – Nvidia Corporation, California

Specialize in Machine Learning
B.Sc. - Drexel University, USA
PhD – Stanford University, USA




Contributions of the Study

Technical Contribution

1. New Architecture – Binary Classification Keras Neural Network Model
2. Accuracy Improvement – New Hybrid Model Implementation
3. Visualization based user interaction system
4. Knowledge Based System – Multi-Agent Systems

Medical Contribution


1. A portable disease diagnosis tool for doctors to identify risk of patients
2. Identify Cardiovascular Disease in its early stages
3. Visualization Components based clinical data analysis



Limitation and Future Recommendations

Limitation

Limitation 01	Limitation on scope of the cardiovascular risk factors used in platform
The risk factors scope describes the scope of area that cardiovascular prediction system covers. In the platform fifty-nine risk factors were used for the prediction process and cardiovascular risk assessment scope can be expand by adding new risk factor to the system.	
Limitation 02	Restrictions on visualization of clinical trials
The platform output cardiovascular disease prediction stage assessment for the physician and it only include the text and charts. In future, the platform can be enhanced to provide image classification for further analysis of the cardiovascular disease prediction.	
Limitation 03	Platform only restrict for the key success factors of a cardiovascular prediction platform
The platform majorly focused on performance key factors and accuracy level of the system. Furthermore, platform can be expanded to improve the new key factors and address other key factors such as scalability and performance.	





Future Enhancements

Enhancement 01	Use more risk variables for analysis the diagnosis in wide range.
By adding more risk variables will increase the diagnosis accuracy level and scope of the diagnosis.	
Priority	High Level Priority
Enhancement 02	Provide access to more web service models
Expand the platform to support more machine learning web service modules which use for predictions. This will help to enhance the system performance and scalability of the platform.	
Priority	High Level Priority
Enhancement 03	Improve the clinical diagnosis dashboard
Expand the clinical diagnosis dashboard with new UI components	
Priority	Low Level Priority
Enhancement 04	Add new image processing components for analyze the scan data
Add image processing components to system for analyze the scan image data for diagnose the cardiovascular diseases.	
Priority	High Priority

2019 IEEE International Conference on Computational Science and Engineering (CSE) and IEEE International Conference on Embedded and Ubiquitous Computing (EUC)

IEEE CSE 2019 notification for paper 87 Inbox x



IEEE CSE 2019 <ieeecse2019@easychair.org>

to me ▾

4:48 PM (6 hours ago) ☆ ↶ ⋮

Dear Gayan:

Thank you very much for your contribution to IEEE EUC 2019. Congratulations to your paper 87: "Review : Intelligent Solution for Early Stage Prediction of Cardiovascular Disease Using Machine Learning and Data Analytics" accepted by IEEE CSE 2019 as a full paper.

Registration link is on the conference website.

<http://www.cloud-conf.net/CSE/2019/registration.html>

Please register your paper. The deadline is 6/15 (includes June 15th, Easter time). This is the time that we receive your payment, not the time that you start to pay. As you know, wire or deposit takes several days to finish the payment. If you don't receive your payment before 6/15, a late fee \$200 will be applied. All accepted papers need to pay full registration fee.

Please prepare your camera ready version according to the comments and submit the camera ready version to IEEE Author Kit.

<https://ieeecs.org/#/auth/login?ak=1&pid=5jWu5hdOiXb5GQ3YeKCJcr>

The deadline is also 6/15. If you registered before 6/15, but didn't submit camera ready paper before 6/15, you still need to pay \$200 late fee. The purpose for this rule is to make sure we can finish the proceeding on time.

We invite you to attend the joint conferences and make your paper oral presentation. Please note that an on-site oral presentation is mandatory for your paper publishing. You may plan your trip accordingly. For IEEE CSE 2019, this email serves as the formal acceptance letter. There is no more other letter issued.

If you have any questions or queries about IEEE CSE/EUC 2019, please contact us by email.

Email: qiuhan1989@gmail.com

Best,

Chairs of IEEE CSE/EUC 2019



IEEE



STC SMART COMPUTING



IEEE computer society





Thank You

Questions and Answers